November 2009, Volume 20, Issue 9, pp 1617-1622,
Open Access This content is freely available online to anyone, anywhere at any time.
Date: 04 Aug 2009
Metformin use and prostate cancer in Caucasian men: results from a population-based case–control study
Metformin is a commonly used medication for type II diabetes mellitus. Epidemiologic studies have suggested a decreased relative risk of cancer with metformin use, and preclinical studies of prostate cancer (PCa) have shown antitumor activity with metformin. In this study, we explore the relationship between metformin use and PCa risk in a population-based case–control study.
Cases were men aged 35–74 years diagnosed with PCa between 2002 and 2005 in King County, Washington. Controls were frequency matched by age and identified by random digit dialing. Use of metformin was determined from in-person questionnaires regarding medical and prescription history. The relationship of metformin use with PCa risk was evaluated using logistic regression.
A total of 1,001 cases of PCa and 942 controls were available for analysis. In Caucasian men, metformin use was more common in controls than in cases (4.7 vs. 2.8%, p = 0.04), resulting in a 44% risk reduction for PCa (adjusted OR = 0.56; 95% CI 0.32–1.00). No association was seen in African-American men.
Metformin use was associated with a borderline significant decrease in the relative risk of PCa in Caucasians. Further study into this relationship is needed to confirm the association and determine the underlying pathways involved.
Ries L, Melbert D, Krapcho M, Stinchcomb D, Howlader N, Horner M et al. (2008) SEER cancer statistics review, 1975–2005, based on November 2007 SEER data submission, posted to the SEER web site. Cited; available from: http://seer.cancer.gov/csr/1975_2005/
Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA (2009) The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 8(1):88–96PubMed
Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66(21):10269102–10269173CrossRef
Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN (2008) The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila Pa) 1(5):369–375
Top 200 Generic Drugs by Units in 2006. Drug Topics
Centers for Disease Control and Prevention (CDC) (2008) State-specific incidence of diabetes among adults–participating states, 1995–1997 and 2005–2007. MMWR Morb Mortal Wkly Rep 57(43):1169–1173
- Metformin use and prostate cancer in Caucasian men: results from a population-based case–control study
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Cancer Causes & Control
Volume 20, Issue 9 , pp 1617-1622
- Cover Date
- Print ISSN
- Online ISSN
- Springer Netherlands
- Additional Links
- Prostate cancer
- Case–control study
- Disease risk
- Population based
- Industry Sectors
- Author Affiliations
- 1. Department of Urology, University of Washington School of Medicine, Seattle, WA, USA
- 2. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M4-B874, Seattle, WA, 98109-1024, USA
- 3. Department of Epidemiology, University of Washington School of Public Health, Seattle, WA, USA